Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Random

Display 15 Products per page

V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
VB-111
Read More
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

from the Phase III GLOBE study.
April 13, 2016
Find out more
Afinitor
Read More
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
March 6, 2019
Find out more
RSV preF vaccine
Read More
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.
October 5, 2018
Find out more
Kynamro
Read More
Kynamro (mipomersen sodium) was the first antisense therapy to enter the dyslipidemia market. It is marketed by Kastle Therapeutics and is approved in the US for the treatment of homozygous familial hypercholesterolemia (HoFH).
June 22, 2018
Find out more
Sotagliflozin
Read More
Sotagliflozin (Lexicon/Sanofi) is an orally administered drug currently being investigated for the treatment of type 1 and type 2 diabetes. It is a dual inhibitor of the sodium-glucose cotransporter-1 (SGLT-1) and SGLT-2 transporters.
November 7, 2017
Find out more
Tymlos
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.
March 9, 2018
Find out more
OncoVAX
Read More
OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery.
December 11, 2017
Find out more
Toujeo
Read More
Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.
November 7, 2017
Find out more
Tezacaftor/Ivacaftor
Read More
Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.
September 14, 2017
Find out more
NovoEight
Read More
NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
May 4, 2018
Find out more
Prolia
Read More
Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis.
March 9, 2018
Find out more
Ultibro
Read More
Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.
April 11, 2016
Find out more
Taltz
Read More
Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17.
May 18, 2018
Find out more
solithromycin
Read More
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.
June 19, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *